



# Drug Coverage Decision for BC PharmaCare

## About PharmaCare

BC PharmaCare is a publicly funded drug plan that helps B.C. residents pay for most prescription drugs and pharmacy services, and some medical devices and supplies.

## Details of Drug Reviewed

<b>Drug</b>	iptacopan
Brand name	Fabhalta®
Dosage form(s)	200 mg capsules
Manufacturer	Novartis Pharmaceuticals Canada Inc.
<b>Submission type</b>	<b>New Submission</b>
Indication reviewed	For the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).
Canada's Drug Agency (CDA-AMC) Reimbursement Reviews	CDA-AMC recommended: <b>to Reimburse with clinical criteria and/or conditions.</b> Visit the CDA-AMC website for more <a href="#">details</a> .
Drug Benefit Council (DBC)	The DBC did not review iptacopan.  The DBC screens drug submissions under review by CDA-AMC to determine whether a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the Canadian Drug Expert Committee (CDEC) recommendation and an internal review only. Since iptacopan is similar to pegcetacoplan which was previously reviewed by DBC on May 1, 2023, for PNH, the Ministry may accept the CDEC's recommendation for pegcetacoplan.
<b>Drug Coverage Decision</b>	<b>Non-benefit</b>
Date	April 13, 2026

Reason(s)	<ul style="list-style-type: none"> <li>• Iptacopan for PNH demonstrated clinical benefit in adult patients with residual hemolytic anemia. However, iptacopan was compared to a C5 inhibitor which is not a relevant comparator for second line therapy.</li> <li>• At the submitted price iptacopan was not considered cost-effective for PNH. CDEC recommended that the price of iptacopan should not exceed the price of pegcetacoplan. The Ministry participated in the pan-Canadian Pharmaceutical Alliance negotiations with the manufacturer which could not address the concerns identified by the CDEC with respect to the cost-effectiveness and value for money.</li> </ul>
-----------	--

### The drug review process in B.C.

A manufacturer submits a request to the Ministry of Health (the Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry by considering:

- whether the drug is safe and effective
- advice from a national group called [Canada's Drug Agency - L'Agence des médicaments du Canada \(CDA-AMC\)](#)
- what the drug costs and whether funding it provides good value to the province
- ethical considerations of covering and not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a BC PharmaCare coverage decision by taking into account:

- existing BC PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- drugs already covered by BC PharmaCare that treat similar medical conditions
- the overall cost of covering the drug

Visit [BC PharmaCare](#) and [Drug reviews](#) for more information.

**This document is intended for information only.**

It does not take the place of advice from a physician or other qualified health care provider.